30 November 2017
UCL spinout company, Puridify Limited, developers of bioprocessing technologies to significantly advance industrial biomolecule manufacture has been acquired by GE Healthcare.
Puridify is developing FibroSelect , a novel nanofiber-based platform purification technology for the biopharmaceutical industry. This technology is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing, promising faster mass transfer, scalability and ease of use.
The FibroSelect platform is expected to improve productivity in the process development (PD) phase and small-scale manufacturing for a wide variety of biopharmaceutical applications. GE Healthcare will invest further to bring Puridify’s platform to commercialisation, fully integrating it within the broad range of bioprocess purification products already available at GE Healthcare.
Puridify’s technology was originally developed at UCL’s department of Biochemical Engineering and was supported by investment from UCLB, Touchstone Innovations and SR One and UCLB since 2014.
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology commercialisation company that supports research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit: www.uclb.com